Supreme Court scrutinizes the feasibility of state cancer lawsuits against glyphosate maker amid preemption debate

On Monday, the United States Supreme Court convened to hear arguments in the case identified as Monsanto v. Durnell, a dispute that pits the doctrine of federal preemption against the longstanding ability of individual states to permit consumers to sue manufacturers for alleged failures to warn about product hazards, specifically the alleged carcinogenicity of glyphosate, the active ingredient in the widely used Roundup herbicide and related products now owned by Bayer.

During the hearing, the justices directed a series of probing inquiries toward the legal counsel representing the former Monsanto Company, seeking clarification on the extent to which the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) might supersede state tort claims, while simultaneously exposing the tension between a regulatory framework that ostensibly controls pesticide safety and a judicial system that must reconcile disparate statutory interpretations with the practical realities of litigation over alleged health impacts.

Although the Court has not rendered a decision, the proceedings have highlighted the paradox that a federal regulatory regime designed to evaluate and mitigate risks associated with chemicals such as glyphosate can be invoked both to shield manufacturers from state-level accountability and to question the adequacy of the very safeguards that the agency purports to enforce, thereby underscoring a systemic inconsistency that has persisted since the product’s introduction.

The broader implication of the Court’s questioning suggests that, should the justices affirm the preemption argument, thousands of pending and future state lawsuits alleging that exposure to glyphosate caused cancer could be dismissed on procedural grounds, effectively placing the burden of proof and remedial responsibility squarely on federal agencies whose historical track record of decisive action on such matters has been, at best, uneven.

Observers note that the outcome of this preemption debate may not only influence the legal landscape for pesticide manufacturers but also serve as a litmus test for the capacity of the United States’ institutional architecture to reconcile consumer protection with corporate interests, a reconciliation that, given the Court’s line of questioning, appears as precarious as the regulatory oversight it purports to evaluate.

Published: April 28, 2026